首页> 美国卫生研究院文献>other >Preclinical Studies To Understand Nanoparticle Interaction with the Immune System and Its Potential Effects on Nanoparticle Biodistribution
【2h】

Preclinical Studies To Understand Nanoparticle Interaction with the Immune System and Its Potential Effects on Nanoparticle Biodistribution

机译:临床前研究以了解纳米粒子与免疫系统的相互作用及其对纳米粒子生物分布的潜在影响。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Nanoparticles have unique physicochemical properties which make them promising platforms for drug delivery. However, immune cells in the bloodstream (such as monocytes, platelets, leukocytes, and dendritic cells) and in tissues (such as resident phagocytes) have a propensity to engulf and eliminate certain nanoparticles. A nanoparticle’s interaction with plasma proteins (opsonins) and blood components (via hemolysis, thrombogenicity and complement activation) may influence uptake and clearance and hence potentially affect distribution and delivery to the intended target sites. Nanoparticle uptake by the immune cells is influenced by many factors. Different nanoparticles have been shown to act on different pathways, while various characteristics/properties also affect which pathway is employed for particle internalization. Nanoparticle protein binding occurs almost instantaneously once the particle enters biological medium, and the physical properties of such a particle–protein complex are often different than those of the formulated particle. These new properties can contribute to different biological responses and change nanoparticle biodistribution. Therefore, in the situation when specific delivery to immune cells is not desired, the ideal nanoparticle platform is the one whose integrity is not disturbed in the complex biological environment, which provides extended circulation in the blood to maximize delivery to the target site, is not toxic to blood cellular components, and is “invisible” to the immune cells which can remove it from circulation. This review discusses the most recent data on nanoparticle interactions with blood components and how particle size and surface charge define their hematocompatibility. This includes properties which determine particle interaction with plasma proteins and uptake by macrophages. We will also provide an overview of in vitro methods useful in identifying interactions with components of the immune system and the potential effects of such interaction on particle distribution to tissues.
机译:纳米粒子具有独特的理化性质,使其成为有希望的药物递送平台。但是,血液中的免疫细胞(如单核细胞,血小板,白细胞和树突状细胞)和组织中的免疫细胞(如常吞噬细胞)具有吞噬和消除某些纳米颗粒的倾向。纳米粒子与血浆蛋白(调理素)和血液成分(通过溶血,血栓形成和补体激活)的相互作用可能会影响摄取和清除,因此可能会影响到预期目标部位的分布和递送。免疫细胞对纳米颗粒的吸收受许多因素影响。已经显示出不同的纳米颗粒作用于不同的途径,而各种特性/性质也影响哪种途径用于颗粒内在化。一旦粒子进入生物介质,纳米粒子蛋白质的结合几乎即刻发生,这种粒子-蛋白质复合物的物理特性通常不同于配制粒子的物理特性。这些新特性可以促进不同的生物学反应并改变纳米颗粒的生物分布。因此,在不需要向免疫细胞的特异性递送的情况下,理想的纳米颗粒平台是在复杂的生物环境中其完整性不会受到干扰的平台,该平台提供了血液中的延长循环以最大程度地递送至靶位点,对血液细胞成分有毒,对免疫细胞“不可见”,可将其从循环系统中清除。这篇评论讨论了有关纳米粒子与血液成分相互作用以及粒子大小和表面电荷如何定义其血液相容性的最新数据。这包括确定颗粒与血浆蛋白相互作用以及巨噬细胞摄取的特性。我们还将概述可用于识别与免疫系统组成部分相互作用的体外方法,以及此类相互作用对组织中微粒分布的潜在影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号